For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Tildrakizumab - Psoriasis
PAD Profile : Tildrakizumab - Psoriasis
Traffic Light Status
Status 1 of 1.
Guidelines
The following guidelines are available for this indication.
Other Drugs
- Adalimumab
- Etanercept
- Infliximab
- Ustekinumab (Psoriasis)
- Secukinumab
- Apremilast
- Ixekizumab
- Brodalumab (Psoriasis)
- Guselkumab (Psoriasis)
- Certolizumab pegol
- Risankizumab
Other Indications
No indications returned.
Additional Documents
Committee Recommendations
The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed the reviewed and updated high cost immunomodulator psoriasis treatment pathway.
The Surrey Heartlands ICS Area Prescribing Committee have agreed an update of the Psoriasis High Cost immunomodulator Drug Treatment Pathway.
The pathway has been updated following guidance from the Regional Medicines Optimisation Committee in May 2020, in relation to the sequential use of biologic medicines. The agreed process and associated documentation is saved here https://surreyccg.res-systems.net/PAD/Search/DrugConditionProfile/6549
The Surrey & North West Sussex Area Prescribing Committee (APC) recommends tildrakizumab as a treatment option in adult patients with moderate to severe plaque psoriasis in line with NICE TA 575 (April 2019)
Tildrakizumab is a payment by results excluded medicine and initiation and subsequent monitoring of response will be by the dermatology specialist service. Blueteq forms for initiation and continuation will be available for completion by specialist teams.
Tildrakizumab will be considered as RED on the traffic light system
Primary care prescribers should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication.